SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Merck
MRK 108.23-0.9%3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Brian Malloy who wrote (487)1/21/1998 1:07:00 AM
From: Bruce Russell  Read Replies (2) of 1580
 
Interestingly, Merck's asthma medication, Singulaire, is from a class of drugs that have caused liver damage. The FDA is being very slow to approve it. Merck doesn't bring unsafe drugs to market. From what I hear, this will be a significant advance in asthma therapy for a lot of people: one pill per day, instead of inhalers on demand.

This could be one very big drug.

Also, the Maxalt for migraine is the first oral migraine medication with the efficacy of an injectable. It will be a very big drug.

These drugs need to get out of the gate fast.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News